MedTrace Logo

Memantine for Enhanced Stroke Recovery

NCT02144584 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-22

No results posted yet for this study

Summary

This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and upper extremity weakness are randomized to either drug or placebo

Conditions

Interventions

DRUG

Memantine XR

The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.

DRUG

Placebo (for memantine)

Placebo to be capsuled to look identical to active drug (memantine)

Sponsors & Collaborators

Principal Investigators

  • Alicia Bennett, D.O. · University of Utah

  • Jennifer Majersik, M.D. · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02144584 on ClinicalTrials.gov